HDAC/SIRT Screening and Profiling Services

In addition to many HDAC products, BPS Bioscience offers biochemical and cell-based HDAC Screening and Profiling services. A detailed report is included with each order. Using these services you can:

  • Screen for inhibitors/targets using our panel of 11 HDACs and 4 Sirtuins
  • Select from IC50 determination and single point concentrations
  • Receive data within days of compound submission
  • Perform follow-up studies using the same proteins manufactured in-house
  • Get questions answered or project guidance in a time-efficient manner
Biochemical Assay Format: 
This assay method eliminates dealing with the radioactivity, extraction, and chromatography aspects of other assays. Only two simple steps on a microtiter plate are needed to analyze HDAC activity. First, an HDAC fluorometric substrate is incubated with purified HDAC enzyme. The deacetylation catalyzed by HDAC sensitizes the resulting product to subsequent treatment with the developer releases a fluorophore that is easily measured on a fluorescence reader.

Cell Based Assays: 
We can perform assays in a variety of tumor cell lines such as A549 and Hela. We can also perform assays in any cell line of your choosing.

Contact BPS today to learn more about our HDAC services. 

Background: 

Deacetylases, as the name implies, are enzymes that remove acetyl groups from protein substrates. The most well studied deacetylases are histone deacetylases (HDACs). HDACs oppose the effects of histone acetyltransferases (HATs), restoring the positive charge of the histone tail lysine residue. Removal of the acetyl group results in a more tightly compacted, heterochromatin conformation, thereby negatively regulating gene expression. There are four classes of HDAC enzymes. Classes I, II, and IV contain the classic HDAC enzymes, whereas Class III contains the sirtuin enzymes, which require the cofactor NAD+ for their activity.

 

HDAC activity is often disrupted in cancer and neurological disorders, and therefore, HDACs are an active drug target. Several HDAC inhibitors have received FDA approval as anti-cancer drugs, and dozens more are in clinical trials.

New studies indicate that HDAC inhibitors can enhance the effects of cancer immunotherapy. When coupled with PD-1 immunotherapy, HDAC inhibitors like Romidepsin can help increase T cell pro-inflammatory chemokine expression and activity. This new therapeutic strategy has the potential to treat lung cancer patients. In addition to cancer, treatment with HDAC inhibitors in mice have been linked to delayed onset of Huntingtins disease and improved motor and cognitive phenotypes. 

BPS was the first company to offer a full suite of active HDAC and Sirtuin proteins. In addition to high purity enzymes, BPS provides isotype-specific assay kits, as well as a number of HDAC  inhibitors/activators and substrates for all of the HDAC classes.

 Related Technologies:

  • Fluorescence Intensity

Contact us today for more information about our Screening and Profiling Services. Tailor our services to meet your needs: Learn more about our Custom Services.